These are top 10 stocks traded on the Robinhood UK platform in July
DURHAM, N.C. - Humacyte, Inc. (NASDAQ:HUMA), a $397.59 million market cap biotech company specializing in implantable bioengineered human tissues, has announced the publication of a Budget Impact Model for its product Symvess in the Journal of Medical Economics. According to InvestingPro data, the company’s stock has seen a -38.81% return year-to-date, currently trading near $3.09. The model suggests that Symvess, a bioengineered vascular conduit for arterial repair, could lead to cost savings for trauma centers and third-party payers by reducing amputation and infection rates.
The study, based on data from the PROOVIT vascular trauma registry and other sources, estimated that the per-patient cost of using Symvess at Level I trauma centers would be $121,615, which includes the product’s purchase price of $29,500. This is compared to higher costs associated with other graft types, such as cryopreserved allograft at $154,722 and prosthetic graft at $137,213.
For third-party payers, the model also showed a cost advantage with Symvess, estimating per-patient costs at $94,165 compared to $181,127 for prosthetic grafts. The economic benefits are primarily attributed to the lower rates of vascular conduit infection and amputation associated with Symvess use. Despite these promising product economics, InvestingPro analysis indicates the company faces significant financial challenges, with an EBITDA of -$105.28 million in the last twelve months and a weak overall financial health score.
The U.S. Food and Drug Administration (FDA) granted full approval for Symvess on December 19, 2024, for adults requiring urgent vascular repair to avoid limb loss when an autologous vein graft is not feasible. Symvess has been used in various traumatic injuries, demonstrating high rates of blood flow and low rates of amputation and infection.
This publication is part of Humacyte’s effort to demonstrate the economic value of Symvess to healthcare decision-makers. It complements clinical efficacy and safety results published previously in JAMA Surgery. With earnings expected in 11 days and analysts setting price targets ranging from $6 to $25, investors seeking deeper insights can access comprehensive analysis and 6 additional key ProTips through InvestingPro’s detailed research reports, available as part of its coverage of 1,400+ US stocks.
The information in this article is based on a press release statement from Humacyte, Inc.
In other recent news, Humacyte has announced several key developments. The company received full FDA approval for its bioengineered tissue product, Symvess, for use in urgent revascularization cases where traditional vein grafts are not feasible. This approval allows Humacyte to commence commercial shipments of Symvess, which is intended to aid in extremity arterial injuries and has shown promising results in clinical studies. In addition to this, Humacyte secured a U.S. patent for its bioreactor system, crucial for producing Symvess and other bioengineered tissues, extending protection until 2040.
Humacyte is also expanding its collaborative efforts with Pluristyx to develop the BioVascular Pancreas, a potential treatment for insulin-dependent diabetes. Moreover, the company is preparing to file an Investigational New Drug application with the FDA for a small-diameter acellular tissue-engineered vessel intended for coronary artery bypass grafting. Analyst Bruce D. Jackson from Benchmark reaffirmed a Buy rating for Humacyte, citing optimism about the adoption of Symvess and the company’s ongoing research partnerships. Humacyte’s early launch activities are reportedly progressing well, with an increasing number of hospitals engaging in the Value Analysis Committee process.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.